London, 13 August 2014: TechNavio, the independent tech-focused global research firm, has published a report on the Global Multiple Sclerosis Drugs Market 2014-2018, which is expected to grow at a CAGR of 5.56 percent during the forecast period of 2013-2018.
Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in the communication and coordination functions of the body
Key Market Drivers
- Unmet Medical Needs
- Robust Drug Pipeline
- Increase in Patient Population
- Increase in PAPs
Key Market Trends
- Introduction of Disease-modifying Drugs
- Shift Toward Oral Drugs
- Rise in Awareness Programs
- Increase in Rehabilitation Programs
- Use of Off-label Drugs
Key Vendors
- Bayer AG
- Biogen Idec Inc.
- Merck Serono SA
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
“Introduction of disease-modifying drugs as a treatment option is one of the potential trends emerging in this market. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis,” says Faisal Ghaus, Vice President of TechNavio.
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
